IP Library Granted Patent US 9,145,381
Granted Patent B2
US 9,145,381 · App. 13/132,013 · Granted Sep 29, 2015

Derivative of [(3-hydroxy-4-pyron-2-yl)-methyl]-amine and use thereof as anti-neoplastic drugs

Inventors: Mirco Fanelli (Urbino, IT); Vieri Fusi (Urbino, IT)
Assignee: Universita' Degli Studi Di Urbino
C07D309/40C07D405/14C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,145,381
App. No.
13/132,013
Granted
Sep 29, 2015
Kind
B2
Abstract

The present invention relates to compounds having general formula (I), i.e. poly-alkyl-bis-maltolic molecules and in particular to derivates of [(3-hydroxy-4-pyron-2-yl)methyl]-amine and pharmaceutically acceptable salts thereof, and to the use thereof as anti-neoplastic drugs, in particular, for the preparation of a medicament for the treatment of neoplastic diseases.

Claims (22)

1. Compounds having Formula I:

wherein:

X 1 , X 2 , X 3 , X 4 =NR 3 , O

R 3 =H, C m H 2m+1 , m=1, 2, 3, 4, 5, 6

n, f, 1, v=0,1

j, k, q, t, z=1, 2

R 1 , R 2 =C m H 2m+1 , m=1, 2, 3, 4, 5, 6

or alternatively form a ring and have the following meaning:

wherein:

Y=NR 3 , O

R 3 =H, C m H 2m+1 , m=1, 2, 3, 4, 5, 6

p=0, 1, 2, 3, 4;

s=0, 1, 2

r=1,2

and pharmaceutically acceptable salts thereof.

2. A method of preparing a medicament, comprising:

combining a predetermined dosage of a compound according to claim 1 with at least one of a pharmaceutically acceptable carrier, stabiliser, diluent, excipient and combinations thereof.

3. A method of treating a patient, comprising:

administering an antibiotic comprising a predetermined concentration of a compound according to claim 1 .

4. A method of treating a primary tumour, the method comprising:

administering a predetermined dosage of a compound according to claim 1 to the primary tumour to impair cell cycle and programmed cell death;

wherein the primary tumour is at least one of rhabdomyosarcoma, leukaemias and lymphomas.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2011
From: MIRCO FANELLI; FUSI, VIERI
To: UNIVERSITA' DEGLI STUDI DI URBINO
Reel/Frame 027104/0991 →
Priority Claims (1)
IT TO2008A0888 · Nov 28, 2008 · national
Continuity (1)
Related Publication 20120035255A1 · Feb 9, 2012